Related Experiment Video
Updated: Mar 29, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review
Yuanchao Xie, Comfort Alicha Ogah, Xiangrui Jiang
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, 201203, P.R. China. jsshen@mail.shcnc.ac.cn.
Abstract:
Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Inhibitors of Bacterial DNA Synthesis
Subviral Agents
Viruses with RNA Genomes
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

